Clinical TrialJul 30, 2026, 06:08 AM
Alterity Secures FDA Registrational Pathway for ATH434 in MSA
AI Summary
Alterity Therapeutics announced that its End-of-Phase 2 meeting with the FDA confirmed a clear registrational pathway for ATH434 in Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, combined with confirmatory evidence, could support approval, with Phase 3 initiation planned by year-end 2026. The company reported a cash balance of A$37.3 million as of June 30, 2026, and received an A$3.98 million R&D tax refund post-quarter. Other updates include a new board appointment and a share consolidation.
Key Highlights
- FDA End-of-Phase 2 meeting confirmed a registrational pathway for ATH434 in MSA.
- FDA agreed a single pivotal Phase 3 trial plus confirmatory evidence could support approval.
- Pivotal Phase 3 trial activities for ATH434 are on track to initiate by year-end 2026.
- Cash balance was A$37.3 million as of June 30, 2026.
- Operating cash outflows for the quarter were A$7.72 million.
- Received A$3.98 million Australian R&D Tax Incentive refund subsequent to quarter end.
- Estimated 5.2 quarters of funding available based on current operating cash flows.
- Ms Ann Cunningham appointed to the Board of Directors.
Price Impact
More from ATHE